258 related articles for article (PubMed ID: 12593999)
21. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
[TBL] [Abstract][Full Text] [Related]
22. [Should infertile women with polycystic ovarian syndrome be treated with metformine?].
Massin N; Galey J; Basille C; Théron-Gérard L; Bry-Gauillard H; Cédrin-Durnerin I; Hugues JN
Gynecol Obstet Fertil; 2003 Mar; 31(3):265-74. PubMed ID: 12770812
[TBL] [Abstract][Full Text] [Related]
23. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
24. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.
Kocak M; Caliskan E; Simsir C; Haberal A
Fertil Steril; 2002 Jan; 77(1):101-6. PubMed ID: 11779598
[TBL] [Abstract][Full Text] [Related]
25. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
[TBL] [Abstract][Full Text] [Related]
26. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
27. Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome.
Morris RS; Karande VC; Dudkiewicz A; Morris JL; Gleicher N
Fertil Steril; 1999 Mar; 71(3):452-6. PubMed ID: 10065781
[TBL] [Abstract][Full Text] [Related]
28. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
29. Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome.
Bützow TL; Kettel LM; Yen SS
Fertil Steril; 1995 Jun; 63(6):1200-3. PubMed ID: 7750589
[TBL] [Abstract][Full Text] [Related]
30. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
Elkind-Hirsch KE
Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
[TBL] [Abstract][Full Text] [Related]
31. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
32. The number of follicles and ovarian volume in the assessment of response to clomiphene citrate treatment in polycystic ovarian syndrome.
Fiçicioğlu C; Api M; Ozden S
Acta Obstet Gynecol Scand; 1996 Nov; 75(10):917-21. PubMed ID: 9003093
[TBL] [Abstract][Full Text] [Related]
33. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.
Cataldo NA; Abbasi F; McLaughlin TL; Basina M; Fechner PY; Giudice LC; Reaven GM
Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076
[TBL] [Abstract][Full Text] [Related]
34. Decline in insulin-like growth factor I levels after clomiphene citrate does not correct hyperandrogenemia in polycystic ovary syndrome.
Fiad TM; Smith TP; Cunningham SK; McKenna TJ
J Clin Endocrinol Metab; 1998 Jul; 83(7):2394-8. PubMed ID: 9661617
[TBL] [Abstract][Full Text] [Related]
35. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
Stabile G; Borrielli I; Artenisio AC; Bruno LM; Benvenga S; Giunta L; La Marca A; Volpe A; Pizzo A
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):177-82. PubMed ID: 24814528
[TBL] [Abstract][Full Text] [Related]
36. Androgen excess contributes to altered growth hormone/insulin-like growth factor-1 axis in nonobese women with polycystic ovary syndrome.
Wu X; Sallinen K; Zhou S; Su Y; Pöllänen P; Erkkola R
Fertil Steril; 2000 Apr; 73(4):730-4. PubMed ID: 10731533
[TBL] [Abstract][Full Text] [Related]
37. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Song J; Shen H; Li J; Huang Z; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
[TBL] [Abstract][Full Text] [Related]
38. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
Kolodziejczyk B; Duleba AJ; Spaczynski RZ; Pawelczyk L
Fertil Steril; 2000 Jun; 73(6):1149-54. PubMed ID: 10856473
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.
Zhang HY; Guo CX; Zhu FF; Qu PP; Lin WJ; Xiong J
Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387
[TBL] [Abstract][Full Text] [Related]
40. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease.
Dereli D; Dereli T; Bayraktar F; Ozgen AG; Yilmaz C
Endocr J; 2005 Jun; 52(3):299-308. PubMed ID: 16006724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
